Pharmacokinetics and bioequivalence study of doxycycline capsules in healthy male subjects

Arzneimittel-Forschung/Drug Research

Volumn 57, Issue 6, 2007, Pages 347-351

  Gschwend, Michael H ^a   Martin, Wolfgang ^a   Erenmemişoǧlu, Aydin ^b   Scherm, Margit ^c   Dilger, Carmen ^c   Tamur, Uygur ^d   Kanzik, Ilker ^e,f   Hincal, A Atilla ^e,g  

^a Pharmakin GmbH   (Germany)

^b ERCIYES UNIVERSITY   (Turkey)

^c AAI Deutschland GmbH and Co KG   (Germany)

^d DEVA Holding A   (Turkey)

^e IDE Pharmaceutical Consulting   (Turkey)

^f GAZI UNIVERSITY   (Turkey)

^g HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Antibiotics; CAS 24390 14 5; CAS 564 25 0; Doxycycline hyclate, bioequivalence, pharmacokinetics; Monodoks ; Tetracyclines

Indexed keywords

DOXYCYCLINE; DOXYCYCLINE HYCLATE; MONODOKS; UNCLASSIFIED DRUG;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG ELIMINATION; HALF LIFE TIME; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRAVIOLET RADIATION; UNSPECIFIED SIDE EFFECT;

EID: 34447334564     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296629     Document Type: Article

References (15)

1. Farin D, Piva G, Gozlan I, Kitzes R. High performance liquid chromatography method for the determination of doxycycline in human plasma. Chromatographia. 1998;47: 547-549.
2. Kitzes-Cohen R, Farin D, Laor A, Piva G, Hazan K, Wasserman A, et al. Bioequivalence study of two formulations of doxycycline. Curr Ther Res. 1998;59:315-323.
3. Bethke T. Information und Beratung: Doxycyclin [Information and consulting: doxycyclin]. Deutsche Apotheker Zeitung. 1995;135 (8):692-695.
4. Blume H, Siewert M, Stenzhorn G, Kübel-Thiel K. ZL-Monographie (Entwurf). Doxycyclin: zur Prüfung der Bioverfügbarkeit/ Bioäquivalenz [Central Laboratory Monograph (draft). Doxycyclin: On the testing of bioavailability/ bioequivalence]. Deutsche Apotheker Zeitung. 1987;127 (41):2090-2094.
5. Blume H, Siewert M, Stenzhom G, Kübel-Thiel K. ZL-Monographie zur Prüfung der Bioverfügbarkeit/Bioäquivalenz (Entwurf). Doxycyclin: Indikationsgruppe: Antibiotika/Chemotherapeutika [Central Laboratory Monograph on the testing of bioavailability/bioequivalence (draft). Doxycyclin: Indication group: Antibiotics/chemotherapeutics]. Pharmazeutische Zeitung. 1987;132 (41):2476-2480.
6. Axisa B, Naylor AR, Bell PR F, Thompson MM. Simple and reliable method of doxycycline determination in human plasma and biological tissues. J Chromatogr B Biomed Sci Appl. 2000;744:359-365.
7. Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet 1988;15:355-366.
8. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, et al. Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies. J Pharm Sci. 1992;81:309-312.
9. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, et al. Analytical Methods Validation: Bioavailability, bioequivalence and pharmacokinetic studies. Pharm Res. 1992;9:588-592.
10. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM): Guidance for Industry, Bioanalytical Method Validation, May 2001
11. Note for Guidance on the Investigation of Bioavailability and Bioequivalence Committee for Proprietary Medicinal Products. CPMP/EWP/QWP/1401/98. London; 26 July 2001.
12. Diletti E, Hauschke D, Steinijans VW. Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol. 1992;30 (Suppl 1):51-58.
13. Alsarra IA, Al-Said MS, Al-Khamis KI, Niazy EM, El-Sayed YM, Al-Rashood KA, et al. Comparative bioavailability study of doxycycline hyclate (equivalent to 100 mg doxycycline) capsules (doxycin vs vibramycin) for bioequivalence evaluation in healthy adult volunteers. Int J Clin Pharmacol Ther. 2004;42:373-377.
14. Schulz HU, Steinijans VW. Striving for standards in bioequivalence assessment: a review. Int J Clin Pharmacol Ther Toxicol. 1991;29:293-298.
15. Gardner S. Bioavailability and bioequivalence requirements. Procedures for establishing a bioequivalence requirement. Fed Reg. 1977;42:1624-1653.